A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants

by | Jun 25, 2026 | Clinical Trials | 0 comments

​ Conditions: HNSCC

Interventions: Drug: SKB571

Sponsors: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Not yet recruiting Conditions: HNSCC
Interventions: Drug: SKB571
Sponsors: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *